Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol

International Journal of Gynecological Cancer

Volumn 21, Issue 5, 2011, Pages 846-851

  Powell, C Bethan ^a,e   Chen, Lee May ^b   McLennan, Jane ^a   Crawford, Beth ^a   Zaloudek, Charles ^c   Rabban, Joseph T ^c   Moore, Dan H ^d   Ziegler, John ^a  

^a Cancer Risk Program   (United States)

^b Gynecology Oncology Program   (United States)

^c Institute of Pathology   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

BRCA mutation carriers; Risk reducing salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER RISK; CARCINOMATOUS PERITONITIS; CLINICAL PROTOCOL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CANCER; OCCULT CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCING BILATERAL SALPINGOOOPHORECTOMY; RISK REDUCTION; SALPINGOOOPHORECTOMY; UTERINE TUBE CARCINOMA;

EID: 82955186873     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821bc7e3     Document Type: Article

References (24)

1. Wooster R,Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348:2339-2347. (Pubitemid 36638109)
2. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710. (Pubitemid 32203724)
3. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21:4222-4227. (Pubitemid 46606192)
4. Meeuwissen PA, Seynaeve C, Brekelmans CT, et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol. 2005;97:476-482. (Pubitemid 40614892)
5. DeMichele A, Weber BL. Risk management in BRCA1 and BRCA2 mutation carriers: Lessons learned, challenges posed. J Clin Oncol. 2002;20:1164-1166. (Pubitemid 34177420)
6. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25:2921-2927. (Pubitemid 47123156)
7. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol. 2008;26: 1331-1337.
8. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990. (Pubitemid 47477278)
9. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80-87.
10. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000;18:2728-2732. (Pubitemid 30463555)
11. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: Prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25:1283-1289. (Pubitemid 32917122)
12. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260-1268. (Pubitemid 34177432)
13. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52-56. (Pubitemid 36027101)
14. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615. (Pubitemid 34755668)
15. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer. 2002;38:S15-S17. (Pubitemid 35284376)
16. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23:127-132. (Pubitemid 41702631)
17. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64. (Pubitemid 41815050)
18. Domchek SM, Friebel TM, Garber JE, et al. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomyin a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010;124:195-203.
19. Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:912-939. (Pubitemid 44580192)
20. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-975.
21. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296:185-192.
22. Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian cancerYprone families. Lancet. 1982;2:795-797. (Pubitemid 12068994)
23. Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 1993;71:2751-2755. (Pubitemid 23120050)
24. Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: Implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009;33:1878-1885.